Publications by authors named "Etienne Bastien"
Background: The conventional method of drug development in oncology typically progresses through phase I, phase II and randomized phase III trials. Nevertheless, some recent drug approvals for head and neck cancer (HNC) relied on findings from single-arm phase II trials. This underscores the significance of disease-specific phase I trials as a crucial step in exploring new drugs for HNC patients.
View Article and Find Full Text PDFNeurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization's database.
Front Pharmacol
October 2023
Endocrine therapies (ETs) and inhibitors of cyclin-dependent kinases-4/6 (iCDK4/6s) are a standard treatment in breast cancer. However, data on potential neurocognitive impacts remain inconsistent for ET and are scarce for iCDK4/6s. To evaluate whether ET and iCDK4/6s are associated with neurocognitive impairment (NCI).
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on the psychological impact of COVID-19 on older versus younger cancer patients, specifically looking at PTSD symptoms and Quality of Life (QoL).
- It included 579 patients and used various standardized questionnaires to assess mental health and QoL over a year, with data collected at multiple points during lockdowns and release periods in France.
- Results showed older patients reported fewer PTSD symptoms and insomnia at the beginning, but cognitive complaints increased over time, eventually matching those of younger patients, with no major differences in the overall mental health trajectory between the two age groups.
Introduction: COVID-19 outbreak rapidly spread since early 2020 leading to the implementation of nationwide lockdowns. To cope with this sudden change, management guidelines were quickly published to adapt oncological care, with potential impact on cancer outcomes.
Methods: We conducted a retrospective comparative cohort study to assess the impact of the COVID-19 outbreak in 2020 on cancer outcomes in metastatic patients.
Background: Patients with cancer may be particularly vulnerable to psychological consequences of the COVID-19 pandemic. We studied the prevalence and evolution of posttraumatic stress symptoms (PTSS) in patients with cancer during the pandemic waves, and we investigated factors associated with high symptoms.
Methods: COVIPACT is a 1-year longitudinal prospective study of French patients with solid/hematologic malignancies receiving treatment during the first nationwide lockdown.
Article Synopsis
- - Transverse myelitis (TM) has been linked to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine, but the relationship with other vaccines like Pfizer, Moderna, AstraZeneca, and Novavax is unclear, prompting this study to explore these associations.
- - The research analyzed safety reports from the WHO's VigiBase, focusing on TM cases occurring within 28 days after receiving any FDA or EMA approved SARS-CoV-2 vaccine between December 2020 and March 2022.
- - Results indicated a significant association between both mRNA-based and vector-based vaccines and TM, yet TM is still rare (0.28 cases per million doses), suggesting the overall benefits of vaccination outweigh the risks
Article Synopsis
- The study investigated the impact of the COVID-19 pandemic on patients with cancer, focusing on the occurrence of PTSD symptoms and changes in their medical care during lockdown.
- Conducted in France, the research involved 734 patients and found that 21% experienced PTSD, with higher rates among women and those with treatment adjustments.
- Results showed that PTSD symptoms negatively affected patients’ quality of life, cognition, and increased insomnia, highlighting the need for support during such traumatic events.